These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33619958)

  • 1. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
    Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
    J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
    Kanouni T; Severin C; Cho RW; Yuen NY; Xu J; Shi L; Lai C; Del Rosario JR; Stansfield RK; Lawton LN; Hosfield D; O'Connell S; Kreilein MM; Tavares-Greco P; Nie Z; Kaldor SW; Veal JM; Stafford JA; Chen YK
    J Med Chem; 2020 Dec; 63(23):14522-14529. PubMed ID: 33034194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks.
    Li ZR; Gu MZ; Xu X; Zhang JH; Zhang HL; Han C
    Chin J Nat Med; 2022 Apr; 20(4):241-257. PubMed ID: 35487595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual review of LSD1/KDM1A inhibitors in 2020.
    Fu DJ; Li J; Yu B
    Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LSD1 in drug discovery: From biological function to clinical application.
    Liu HM; Zhou Y; Chen HX; Wu JW; Ji SK; Shen L; Wang SP; Liu HM; Liu Y; Dai XJ; Zheng YC
    Med Res Rev; 2024 Mar; 44(2):833-866. PubMed ID: 38014919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
    Song Y; Zhang H; Yang X; Shi Y; Yu B
    Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
    Li L; Li R; Wang Y
    Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy.
    Fang Y; Liao G; Yu B
    Curr Top Med Chem; 2019; 19(11):889-891. PubMed ID: 31389779
    [No Abstract]   [Full Text] [Related]  

  • 13. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
    Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
    Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
    Ma Y; Zheng Y; Ji Y; Wang X; Ye B
    Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
    [No Abstract]   [Full Text] [Related]  

  • 17. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
    Xu S; Zhou C; Liu R; Zhu Q; Xu Y; Lan F; Zha X
    Bioorg Med Chem; 2018 Sep; 26(17):4871-4880. PubMed ID: 30153955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.